Atlas Wealth Partners LLC Sells 425 Shares of Johnson & Johnson $JNJ

Atlas Wealth Partners LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 12.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,127 shares of the company’s stock after selling 425 shares during the period. Johnson & Johnson makes up about 0.6% of Atlas Wealth Partners LLC’s investment portfolio, making the stock its 26th largest position. Atlas Wealth Partners LLC’s holdings in Johnson & Johnson were worth $478,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. GFG Capital LLC purchased a new position in Johnson & Johnson during the second quarter worth $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth about $48,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter worth about $52,000. Finally, Pandora Wealth Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter worth about $65,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.3%

Shares of JNJ opened at $186.89 on Wednesday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The firm has a fifty day moving average price of $183.64 and a 200-day moving average price of $168.16. The firm has a market capitalization of $450.27 billion, a P/E ratio of 18.04, a P/E/G ratio of 2.19 and a beta of 0.40. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is currently 50.19%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a report on Monday, October 20th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Citigroup raised their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a research note on Friday, October 10th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.